News

Betrixaban, an oral small molecule, inhibits the activity of Factor Xa, which is pivotal in the blood coagulation pathway. The company intends to begin a Phase 3 betrixaban

The move implies that EMA has confirmed the completion of the application and will begin the review procedure. Tofacitinib has been studied in the Phase 3 ORAL (Oral

Flucytosine Capsules are the generic version of Valeant Pharmaceuticals’ Ancobon Capsules and 500 mg strength of Chloroquine Phosphate Tablets, an approved generic version of Sanofi Aventis’ Aralen Tablets.

The multi-center, open label, single arm trial will enroll 50 women with hormone receptor-positive breast cancer that has metastasized to the bone and whose disease has progressed after

Pfizer had entered into a 10-year lease agreement with MIT for over 180,000ft2 in September 2011. Pfizer has planned to switch its research and development, to lay more

The transaction, when completed, is expected to be dilutive to Gilead’s earnings through 2014 and accretive in 2015 and beyond. At present, Pharmasset’s three clinical-stage product candidates to

According to the company, the BioPharm Systems’ new service expands its clinical trial management practice offerings. The solution will help clinical research organizations to reduce cost, boost productivity,

The randomised, placebo controlled Phase I study is intended to assess the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944. Recently, ascending dose Phase

The ascending dose, double-blind, placebo-controlled study in healthy, non-smoking and smoking volunteers is designed to demonstrate the safety, tolerability and pharmacodynamic profile of the drug candidate. The study